Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has signed an agreement to acquire a U.S. Food and Drug Administration Rare Pediatric Disease ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE